Oramed Pharmaceuticals Stock
€2.15
Your prediction
Description Oramed
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company based in Israel. It is focused on the development of oral drug delivery systems. The company's lead drug candidate, ORMD-0801, is an oral insulin capsule used for the treatment of diabetes.
Oramed has completed multiple clinical trials for ORMD-0801, demonstrating its safety and efficacy in reducing blood glucose levels among patients with type 2 diabetes. The company has also recently announced the initiation of clinical trials for ORMD-0901, an oral GLP-1 analog capsule used for the treatment of type 2 diabetes and obesity.
Oramed was founded in 2002 and went public in 2007. Its shares are traded on the Nasdaq Global Market under the symbol ORMP. As of August 2021, the company had a market capitalization of approximately $230 million.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Oramed
sharewise wants to provide you with the best news and tools for Oramed, so we directly link to the best financial data sources.